ES2543174T3 - Composición medicinal para el tratamiento y/o la prevención del cáncer - Google Patents

Composición medicinal para el tratamiento y/o la prevención del cáncer Download PDF

Info

Publication number
ES2543174T3
ES2543174T3 ES11739867.7T ES11739867T ES2543174T3 ES 2543174 T3 ES2543174 T3 ES 2543174T3 ES 11739867 T ES11739867 T ES 11739867T ES 2543174 T3 ES2543174 T3 ES 2543174T3
Authority
ES
Spain
Prior art keywords
cancer
prevention
treatment
medicinal composition
cdrs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11739867.7T
Other languages
English (en)
Inventor
Fumiyoshi Okano
Takanori Saito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Application granted granted Critical
Publication of ES2543174T3 publication Critical patent/ES2543174T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un anticuerpo o un fragmento del mismo, que comprende una región variable de cadena pesada que comprende las CDR de 1 a 3 representadas por las SEC ID Nº: 39, 40 y 41 respectivamente y una región variable de cadena ligera que comprende las CDR de 1 a 3 representadas por las SEC ID Nº 43, 44 y 45, respectivamente, y que tiene una reactividad inmunológica con una proteína de CAPRIN-1.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24

Claims (1)

  1. imagen1
ES11739867.7T 2010-02-04 2011-02-04 Composición medicinal para el tratamiento y/o la prevención del cáncer Active ES2543174T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010023452 2010-02-04
JP2010023452 2010-02-04
PCT/JP2011/052384 WO2011096519A1 (ja) 2010-02-04 2011-02-04 癌の治療及び／又は予防用医薬組成物

Publications (1)

Publication Number Publication Date
ES2543174T3 true ES2543174T3 (es) 2015-08-17

Family

ID=44355513

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11739867.7T Active ES2543174T3 (es) 2010-02-04 2011-02-04 Composición medicinal para el tratamiento y/o la prevención del cáncer

Country Status (16)

Country Link
US (1) US8709418B2 (es)
EP (1) EP2532680B1 (es)
JP (1) JP5845899B2 (es)
KR (1) KR101758117B1 (es)
CN (1) CN102822199B (es)
AU (1) AU2011211684B2 (es)
BR (1) BR112012019098B8 (es)
CA (1) CA2788547C (es)
DK (1) DK2532680T3 (es)
ES (1) ES2543174T3 (es)
HU (1) HUE025678T2 (es)
MX (1) MX340017B (es)
PL (1) PL2532680T3 (es)
PT (1) PT2532680E (es)
RU (1) RU2567657C2 (es)
WO (1) WO2011096519A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2322221T3 (da) 2008-08-05 2014-09-01 Toray Industries Farmaceutisk sammensætning til behandling og forebyggelse af cancer
MX337991B (es) 2008-08-05 2016-03-30 Toray Industries Metodo para detectar cancer.
KR101871704B1 (ko) * 2010-02-04 2018-06-27 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
BR112012018951C8 (pt) 2010-02-04 2020-06-23 Toray Industries anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
AU2011211699B2 (en) 2010-02-04 2015-01-22 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
HUE040012T2 (hu) * 2010-02-04 2019-02-28 Toray Industries Gyógyászati ágens rák kezelésére és/vagy megelõzésére
KR101842893B1 (ko) 2010-02-04 2018-03-28 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
CN103764825B (zh) 2011-08-04 2015-09-02 东丽株式会社 癌的治疗和/或预防用药物组合物
PT2740796T (pt) 2011-08-04 2017-07-26 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
ES2672695T3 (es) 2011-08-04 2018-06-15 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer
MX348579B (es) 2011-08-04 2017-06-20 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
ES2629061T3 (es) 2011-08-04 2017-08-07 Toray Industries, Inc. Método para la detección de cáncer pancreático
KR101968499B1 (ko) 2011-08-04 2019-04-12 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
BR112014002619A2 (pt) 2011-08-04 2018-10-09 Toray Industries, Inc composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica
ES2739380T3 (es) 2012-02-21 2020-01-30 Toray Industries Composición farmacéutica para el tratamiento del cáncer
AU2013223143B2 (en) * 2012-02-21 2017-12-21 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
MX357505B (es) 2012-02-21 2018-07-12 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
IN2014KN01714A (es) * 2012-02-21 2015-10-23 Toray Industries
US9428581B2 (en) 2012-03-30 2016-08-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
PT2832365T (pt) * 2012-03-30 2018-01-24 Toray Industries Composição farmacêutica para o tratamento e/ou prevenção do cancro hepático
WO2014014082A1 (ja) 2012-07-19 2014-01-23 東レ株式会社 癌の検出方法
CA2879185C (en) 2012-07-19 2021-08-24 Toray Industries, Inc. Method for detecting cancer
CA2918989C (en) * 2013-08-09 2021-11-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
WO2018079740A1 (ja) * 2016-10-28 2018-05-03 東レ株式会社 癌の治療及び／又は予防用医薬組成物
KR102120223B1 (ko) 2017-12-08 2020-06-08 세종대학교산학협력단 암의 예방 또는 치료용 의약 조성물
WO2019189780A1 (ja) 2018-03-30 2019-10-03 東レ株式会社 癌の治療及び／又は予防用医薬組成物
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
JP2022537158A (ja) 2019-06-13 2022-08-24 ボルト バイオセラピューティクス、インコーポレーテッド アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用
EP4038053A1 (en) 2019-09-30 2022-08-10 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
EP4048315B1 (en) 2019-10-25 2025-03-12 Bolt Biotherapeutics, Inc. Thienoazepine immunoconjugates, and uses thereof
EP4119157A4 (en) 2020-03-12 2024-03-27 Toray Industries, Inc. MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
CA3175129A1 (en) 2020-03-12 2021-09-19 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CA3175127A1 (en) 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JP7797875B2 (ja) 2020-03-12 2026-01-14 東レ株式会社 癌の治療及び／又は予防のための医薬品
JPWO2021182574A1 (es) * 2020-03-12 2021-09-16
CA3176626A1 (en) 2020-05-08 2021-11-11 David Dornan Elastase-substrate, peptide linker immunoconjugates, and uses thereof
MX2023001679A (es) 2020-08-13 2023-02-22 Bolt Biotherapeutics Inc Inmunoconjugados de pirazolazepina y usos de estos.
AU2022298240A1 (en) 2021-06-23 2024-01-18 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4360648A4 (en) 2021-06-23 2025-10-08 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
EP4378478A4 (en) 2021-07-27 2025-11-12 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
KR20240042415A (ko) 2021-07-27 2024-04-02 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
AU2022319362A1 (en) 2021-07-27 2024-02-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
US20250000995A1 (en) 2021-10-29 2025-01-02 Bolt Biotherapeutics, Inc. Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
AU2023298568A1 (en) 2022-06-30 2025-01-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
JPWO2024043252A1 (es) 2022-08-24 2024-02-29
CN119768181A (zh) 2022-08-24 2025-04-04 东丽株式会社 用于癌的治疗和/或预防的药品
AU2023329564A1 (en) 2022-08-24 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
AU2023334696A1 (en) 2022-08-30 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CN119789868A (zh) 2022-08-30 2025-04-08 东丽株式会社 用于癌的治疗和/或预防的药品
KR20250118852A (ko) 2022-12-23 2025-08-06 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
WO2024173387A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof
WO2024186626A1 (en) 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Aza-bicyclic sting agonist immunoconjugates, and uses thereof
WO2024204325A1 (ja) 2023-03-28 2024-10-03 東レ株式会社 細胞膜タンパク質を検出する方法
EP4691490A1 (en) 2023-03-31 2026-02-11 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
JPWO2025058000A1 (es) 2023-09-13 2025-03-20
WO2026055185A1 (en) 2024-09-04 2026-03-12 Bolt Biotherapeutics, Inc. Sting agonist immunoconjugates and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE340590T1 (de) 1994-07-13 2006-10-15 Chugai Pharmaceutical Co Ltd Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
SK14812000A3 (sk) 1998-04-03 2001-08-06 Chugai Seiyaku Kabushiki Kaisha Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6335170B1 (en) 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
EP1187915A2 (en) 1999-04-02 2002-03-20 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP2003528587A (ja) 1999-10-29 2003-09-30 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ２７個のヒト分泌タンパク質
AU2001261007A1 (en) 2000-03-29 2001-10-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US20040236091A1 (en) 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
WO2002083070A2 (en) 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
AU2002309063B8 (en) 2001-05-11 2008-04-24 Kyowa Kirin Co., Ltd. Artificial human chromosome containing human antibody lambda light chain gene
AU2002311909A1 (en) 2001-05-11 2002-11-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20050003390A1 (en) 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20060121029A1 (en) 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells
EP1572116A4 (en) 2002-11-26 2007-12-12 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
WO2004076682A2 (en) 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
AU2004235382A1 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing AML and MDS differential gene expression
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070048738A1 (en) 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
BRPI0509367A (pt) 2004-03-30 2007-09-11 Glaxo Group Ltd anticorpo, fragmento de ligação de antìgeno, composição farmacêutica, métodos de tratar um paciente humano afligido com uma doença ou distúrbio, de triar um anticorpo, e de detectar hosm em uma amostra biológica, uso de um anticorpo terapêutico ou fragmento de ligação de antìgeno, medicamento, vetor, polunucleotìdeo, célula hospedeira recombinante estavelmente transformada ou transfectada, e, processo para a fabricação de um anticorpo terapêutico
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
RU2297241C2 (ru) * 2004-11-22 2007-04-20 Государственное учреждение Российский научный центр рентгенорадиологии Министерства здравоохранения и социального развития Химерный белок для лечения злокачественных лимфом
EP3698807A1 (en) 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
AU2006214105A1 (en) 2005-02-18 2006-08-24 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
EP1869462B1 (en) 2005-03-11 2013-05-08 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer and endometrial cancer: hepcidin
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
CA2642342A1 (en) 2006-02-14 2007-08-23 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
WO2008073162A2 (en) 2006-08-17 2008-06-19 Cell Signaling Technology, Inc. Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2008031041A2 (en) 2006-09-07 2008-03-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
JP2010023452A (ja) 2008-07-24 2010-02-04 Seiko Epson Corp 印刷装置、及びデータ通信方法
MX337991B (es) 2008-08-05 2016-03-30 Toray Industries Metodo para detectar cancer.
PL2324842T3 (pl) 2008-08-05 2015-08-31 Toray Industries Środek indukujący odporność
DK2322221T3 (da) 2008-08-05 2014-09-01 Toray Industries Farmaceutisk sammensætning til behandling og forebyggelse af cancer
KR101871704B1 (ko) 2010-02-04 2018-06-27 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
KR101842893B1 (ko) 2010-02-04 2018-03-28 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
HUE040012T2 (hu) 2010-02-04 2019-02-28 Toray Industries Gyógyászati ágens rák kezelésére és/vagy megelõzésére
AU2011211699B2 (en) 2010-02-04 2015-01-22 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
BR112012018951C8 (pt) 2010-02-04 2020-06-23 Toray Industries anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
ES2629061T3 (es) 2011-08-04 2017-08-07 Toray Industries, Inc. Método para la detección de cáncer pancreático
PT2740796T (pt) 2011-08-04 2017-07-26 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
BR112014002619A2 (pt) 2011-08-04 2018-10-09 Toray Industries, Inc composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica

Also Published As

Publication number Publication date
BR112012019098A2 (pt) 2018-03-27
MX2012008996A (es) 2012-09-07
US8709418B2 (en) 2014-04-29
JPWO2011096519A1 (ja) 2013-06-13
EP2532680A1 (en) 2012-12-12
PL2532680T3 (pl) 2015-10-30
RU2567657C2 (ru) 2015-11-10
CA2788547A1 (en) 2011-08-11
JP5845899B2 (ja) 2016-01-20
AU2011211684A1 (en) 2012-08-23
AU2011211684B2 (en) 2014-09-25
PT2532680E (pt) 2015-09-14
WO2011096519A1 (ja) 2011-08-11
CA2788547C (en) 2018-06-05
KR101758117B1 (ko) 2017-07-14
DK2532680T3 (da) 2015-07-20
BR112012019098B1 (pt) 2021-07-06
HUE025678T2 (en) 2016-04-28
CN102822199B (zh) 2014-10-15
RU2012137505A (ru) 2014-03-10
KR20120125327A (ko) 2012-11-14
CN102822199A (zh) 2012-12-12
BR112012019098B8 (pt) 2021-08-17
EP2532680A9 (en) 2014-12-17
EP2532680B1 (en) 2015-04-29
MX340017B (es) 2016-06-22
US20120321641A1 (en) 2012-12-20
EP2532680A4 (en) 2013-11-27

Similar Documents

Publication Publication Date Title
ES2564252T3 (es) Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos
AR122771A2 (es) Anticuerpos para el tratamiento del cáncer, conjugado, composición farmacéutica, ácido nucleico y célula huésped
ES2540858T3 (es) Composición farmacéutica para el tratamiento y/o la prevención de cáncer
AR132864A2 (es) UN ANTICUERPO QUE SE UNE ESPECÍFICAMENTE A a-SINUCLEÍNA HUMANA, UN ANTICUERPO HUMANIZADO, UNA FORMULACIÓN FARMACÉUTICA QUE COMPRENDE EL ANTICUERPO, Y LA UTILIZACIÓN DEL ANTICUERPO
MX2020006213A (es) Anticuerpos anti-trem2 y metodos relacionados.
PE20150002A1 (es) Anticuerpos anti-fcrn
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
CU24568B1 (es) Anticuerpo inhibidor de masp-3
PE20140247A1 (es) Anticuerpos anti-cd38
PE20181076A1 (es) Nuevos moduladores y metodos para su uso
PE20140004A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y bortezomib
AR109715A1 (es) Anticuerpos anti-cd27
ES2584956T3 (es) Anticuerpos anti-CD40 y usos de los mismos
PE20131209A1 (es) Anticuerpos anti-fap
CL2016003346A1 (es) Anticuerpos anti-tau humanizados
DOP2017000031A (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso
AR084315A1 (es) Anticuerpos anti-notch1
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
ES2620264T3 (es) Anticuerpos humanizados frente a LIV-1 y el uso de los mismos para tratar el cáncer
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados